David C. Myles - Nov 20, 2023 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Signature
/s/ Shane Kovacs, Attorney-in-Fact
Stock symbol
OLMA
Transactions as of
Nov 20, 2023
Transactions value $
-$196,233
Form type
4
Date filed
11/22/2023, 07:00 PM
Previous filing
Nov 13, 2023
Next filing
Feb 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Award $0 +26.3K +4.68% $0.00 588K Nov 20, 2023 Direct F1, F2
transaction OLMA Common Stock Sale -$101K -6.78K -1.15% $14.87 581K Nov 21, 2023 Direct F3, F4
transaction OLMA Common Stock Sale -$3.06K -200 -0.03% $15.32 581K Nov 21, 2023 Direct F3, F5
transaction OLMA Common Stock Sale -$92.4K -6.65K -1.15% $13.89 574K Nov 22, 2023 Direct F3, F6
holding OLMA Common Stock 12.8K Nov 20, 2023 See Footnote F7
holding OLMA Common Stock 155K Nov 20, 2023 See Footnote F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 75,000 shares, which are subject to vesting upon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on November 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria.
F2 Includes 208 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2023.
F3 The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F4 The weighted average sale price for the transaction reported was $14.87, and the range of prices was between $14.26 and $15.25. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F5 The weighted average sale price for the transaction reported was $15.32, and the range of prices was between $15.28 and $15.35. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F6 The weighted average sale price for the transaction reported was $13.89, and the range of prices was between $13.62 and $14.15. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F7 The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee.
F8 The shares are held by Myles Properties Inc., of which the Reporting Person is President.